Publications by authors named "Mark A Dombroski"

Claim this Profile
D
Discovery, synthesis and SAR of azinyl- and azolylbenzamides antagonists of the P2X₇ receptor.
Chakrapani Subramanyam, Allen J Duplantier, Mark A Dombroski, Shang-Poa Chang, Christopher A Gabel

Bioorg Med Chem Lett· September 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Optimization of the physicochemical and pharmacokinetic attributes in a 6-azauracil series of P2X7 receptor antagonists leading to the discovery of the clinical candidate CE-224,535.
Allen J Duplantier, Mark A Dombroski, Chakrapani Subramanyam, Aimee M Beaulieu, Shang-Poa Chang

Bioorg Med Chem Lett· June 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Orally active and brain permeable proline amides as highly selective 5HT2c agonists for the treatment of obesity.
Kevin K-C Liu, Bruce A Lefker, Mark A Dombroski, Phoebe Chiang, Peter Cornelius

Bioorg Med Chem Lett· April 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Preclinical pharmacokinetics and metabolism of 6-(4-(2,5-difluorophenyl)oxazol-5-yl)-3-isopropyl-[1,2,4]-triazolo[4,3-a]pyridine, a novel and selective p38alpha inhibitor: identification of an active metabolite in preclinical species and human liver microsomes.
Amit S Kalgutkar, Heather L Hatch, Frederick Kosea, Hang T Nguyen, Edna F Choo, Mark A Dombroski

Biopharm Drug Dispos· November 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Structure-activity relationships of triazolopyridine oxazole p38 inhibitors: identification of candidates for clinical development.
Kim F McClure, Michael A Letavic, Amit S Kalgutkar, Christopher A Gabel, Laurent Audoly, Mark A Dombroski

Bioorg Med Chem Lett· August 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Theoretical and experimental design of atypical kinase inhibitors: application to p38 MAP kinase.
Kim F McClure, Yuriy A Abramov, Ellen R Laird, John T Barberia, Weiling Cai, Mark A Dombroski

J Med Chem· September 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Benzimidazolone p38 inhibitors.
Mark A Dombroski, Michael A Letavic, Kim F McClure, John T Barberia, Thomas J Carty

Bioorg Med Chem Lett· February 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Glutathione s-transferase omega 1-1 is a target of cytokine release inhibitory drugs and may be responsible for their effect on interleukin-1beta posttranslational processing.
Ronald E Laliberte, David G Perregaux, Lise R Hoth, Philip J Rosner, Crystal K Jordan, Mark A Dombroski

J Biol Chem· May 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis